Gan Dunnington Named Chief Medical Officer at Pulse Biosciences

Pulse Biosciences Inc. has appointed Gansevoort “Gan” Dunnington, M.D., as its Chief Medical Officer.
 
“On behalf of the company, I am thrilled to welcome Dr. Dunnington to the Pulse Biosciences team,” Pulse Biosciences CEO Kevin Danahy said. “Dr. Dunnington brings a wealth of knowledge, expertise, and experience in the field of cardiothoracic surgery, where he is a leader in pioneering novel less-invasive technologies that improve the lives of patients with atrial fibrillation. We look forward to his leadership and contributions, as we continue to harness the power of nanosecond pulsed field ablation to have a significant and meaningful positive impact on the treatment outcomes of atrial fibrillation, all the while being increasingly patient and physician friendly.”
 
Dunnington is a cardiothoracic surgeon and director of Cardiothoracic Surgery at St. Helena Hospital in Napa Valley (California). He specializes in minimally invasive complex cardiothoracic procedures including the Hybrid Cox-Maze procedure for treating atrial fibrillation (AF). Prior to his St. Helena Hospital tenure, Dunnington was an assistant professor at Stanford University and assistant director of cardiothoracic surgery at El Camino Hospital, a Stanford University affiliate.

Dunnington earned his medical degree from the Medical College of Virginia. He completed his residency at Stanford University, where he served as chief resident of Surgery, and completed a fellowship in cardiothoracic surgery at the University of Virginia.
 
“I believe nsPFA can meaningfully advance the treatment of AF for patients,” Dunnington stated. “Based on my experience using this technology in preclinical studies, I believe the differentiated mechanism of action has the potential to significantly improve the safety and efficacy profile of cardiac ablation procedures and to disrupt the AF surgical device market. I am excited to join the Pulse Biosciences team at this important stage of the product and look forward to helping to bring this differentiated technology to patients and healthcare providers around the world.”
 
Pulse Biosciences is a bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The company is actively pursuing the development of its nsPFA technology for use in treating atrial fibrillation as well as a select few other opportunities currently served by alternative established ablation procedures.